The US Food and Drug Administration (FDA) on Thursday awarded accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, through its breakthrough therapy designation & orphan drug designation.
This approval was granted to BeiGene USA Inc.
Mantle cell lymphoma is a type of non-Hodgkin's lymphoma representing 3-10% of all non-Hodgkin's lymphomas in the US. By the time it is diagnosed, mantle cell lymphoma has usually spread to the lymph nodes, bone marrow as well as other organs.
A single-arm clinical trial of Brukinsa included 86 patients with mantle cell lymphoma with at least one prior treatment. The trial measured the overall response rate of how many patients experienced complete or partial shrinkage of their tumours after treatment.
In the trial, 84% of patients had tumour shrinkage with a median duration of response (time between the initial response to therapy and subsequent disease progression or relapse) of 19.5 months. This trial was supported by an additional single-arm trial that included 32 patients, in which 84% of patients had tumour shrinkage with a median duration of response of 18.5 months.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML